Results 81 to 90 of about 6,419 (213)

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Health Science Reports, 2022
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic.
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam   +3 more
doaj   +1 more source

Enhancing the Outcome of Crystallographic Fragment Screening by Choosing the Optimal Protein Crystal Form

Small Science, Volume 6, Issue 3, March 2026.
The selection of the crystal form impacts crystallographic fragment screening (CFS) hit rates. Almost identical CFS campaigns using monoclinic versus orthorhombic crystals of SARS‐CoV‐2 main protease yield hit rates of 3% and 16%. The higher hit rate correlates with larger solvent channels and a less constrained active site in the orthorhombic form ...
Tatjana Barthel, Jan Wollenhaupt, Laila S. Benz, Patrick Reinke, Linlin Zhang, Melanie Oelker, Frank Lennartz, Helena Taberman, Uwe Mueller, Alke Meents, Rolf Hilgenfeld, Manfred S. Weiss   +11 more
wiley   +1 more source

Symptoms Associated With Detection of Viral Versus Bacterial Pathogens in Outpatients With Lower Respiratory Infections

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Purpose This study aims to identify symptoms that predict a high likelihood of viral infection, so these patients could be triaged for home care to avoid antibiotics. Methods We recruited adults presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent with LRTI. Data collected included demographics,
Mark Ebell, Dan J. Merenstein, Bruce Barrett, Cassie Hulme, Sarah Walters, Caroline Hamer, Michelle Buhr   +6 more
wiley   +1 more source

The association between COVID‐19 and incident gestational diabetes (GDM): A population‐based case–control study of the National Health Insurance Research Database in Taiwan

Journal of Diabetes Investigation, Volume 17, Issue 3, Page 527-534, March 2026.
Our study found no evidence that COVID‐19 infection is linked to gestational diabetes; however, it shows some evidence of an association between vaccination and a reduced risk. ABSTRACT Background Reports suggested that diabetes could be a complication arising from COVID‐19; however, the relationship between COVID‐19 and the development of gestational ...
Liang‐Yu Lin, Chi‐Jen Chen, Mei‐Huei Chen, Chun‐Wei Chen, Pau‐Chung Chen   +4 more
wiley   +1 more source

Effect of Paxlovid on Neurodevelopmental Disorder Diagnosis Outcomes in Offspring of Mothers Infected with SARS-Cov-2 during Pregnancy [PDF]

The onset of the 2020 COVID-19 pandemic brought concern over the effects that this virus would have on pregnancy and fetal outcomes, specifically neurodevelopmental outcomes.
Rogers, Simone
core   +1 more source

Machine Learning‐Guided Repositioning of a SARS‐CoV‐2‐Targeting Molecular Series as Cruzain Inhibitors

ChemMedChem, Volume 21, Issue 2, January 2026.
An ExtraTrees machine learning (ML) model is used to reposition a SARS‐CoV‐2‐directed library of peptidomimetic compounds as cruzain inhibitors for Chagas disease. Potent binders with a novel P1 moiety (for cruzain) are identified and validated by calorimetry.
Rafael F. Lameiro, Luiz F. Barbosa, Evelin R. Cardoso, Beatriz Siqueira Ho, Felipe Cardoso Prado Martins, Bruna C. de Melo, Fabiana Rosini, Anwar Shamim, Priscila M. Souza, Wellington Falcão de Souza, Carlos A. Montanari   +10 more
wiley   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.
ABSTRACT Purpose To describe the characteristics of adults who had a severe coronavirus disease 2019 (COVID‐19) outcome during a timeframe that nirmatrelvir/ritonavir (NMV‐r; Paxlovid) was available, to assess medical eligibility and receipt of NMV‐r before presentation to acute care.
Sylvia Aponte‐Hao, Khanh Vu, Jason R. Randall, Karen J. B. Martins, Phuong Uyen Nguyen, Lynora Saxinger, Jenine Leal, Elissa Rennert‐May, Ellen Rafferty, Tyler Williamson, Scott W. Klarenbach   +10 more
wiley   +1 more source

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies

Molecules
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized ...
Reham F. Barghash, Donato Gemmati, Ahmed M. Awad, Mustafa M. M. Elbakry, Veronica Tisato, Kareem Awad, Ajay Vikram Singh   +6 more
doaj   +1 more source

Paxlovid: A Regulatory Gamble

The American Journal of Medicine, 2023
Miloš D. Miljković, Vinay Prasad
openaire   +4 more sources

Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment [PDF]

Nirmatrelvir (PF-07321332), a first-in-class inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro), was developed by Pfizer under intense pressure during the pandemic to treat COVID-19.
Brewitz, Lennart, Schofield, Christopher J.   +1 more
core   +2 more sources